The Bharat Coking Coal Limited IPO, a subsidiary of Coal India Limited, is receiving massive demand from the market, as the issue has already been announced 16.11 times overall. by the second day of bidding. One of the biggest plus points is the data from the grey market; the BCCL IPO GMP is currently signalling a 47% gain for the investors who will be lucky enough to receive the shares.
BCCl IPO Subscription So Far
As of January 12, i.e., Day 2 of bidding, the BCCL IPO subscription jumped to 16.11 times overall with huge demand across investor categories. The public issue was subscribed 15.81 times in the retail category, 0.36 times in QIB (ex anchor), and 39.64 times in the NII category.
Key Details of Bharat Coking Coal IPO
The Bharat Coking Coal IPO is a book-built issue worth Rs. 1,071.11 crore, consisting entirely of an Offer for Sale (OFS) of 46.57 crore equity shares. Since it is an OFS, the company will not receive fresh funds from the issue; the proceeds will go to the selling shareholder. The price band for the BCCL IPO is Rs. 21 to Rs. 23 per share.
The IPO opened for subscription on January 9 and will close on January 13. The allotment for the IPO will be finalised on January 14 as per the expected date, and the listing is scheduled.
How Much Do You Need to Invest in the BCCL IPO?
The lot size for retail investors is 600 shares, so the retail minimum investment is Rs. 13,800 (600 shares × Rs. 23). Meanwhile, for small HNI, the minimum investment is 15 lots or 9,000 shares worth Rs. 207,000, and for big HNI, it is 73 lots or 43,800 shares worth Rs. 1,007,400.
The issue also includes a reservation of up to 2.33 crore shares for employees, offered at a discount of Rs. 1 per share to the issue price.
BCCL IPO GMP On Day
According to data from the InvestorGain website, the BCCL IPO GMP stood at around Rs. 10.85 as of early morning trading. Based on the upper price band of Rs. 23, the estimated listing price works out to Rs. 33.85 per share, indicating an expected gain of 47.17% on listing.
Will This BCCL IPO Be the Next Big Thing?
Market experts say the BCCL IPO should be viewed from a strategic perspective, not just as a PSU listing.
“BCCL is the single largest domestic supplier of coking coal, accounting for roughly half of India’s indigenous coking coal production, with annual output running at over 40 million tonnes. This assumes significance when placed against India’s structural dependence on imports, which still meet nearly 80-85% of the country’s total coking coal requirement. As crude steel capacity continues to expand toward the government’s 300-mt aspiration, security of metallurgical coal supply becomes a strategic variable.” said Harshal Dasani, Business Head, INVasset PMS.
“From a financial standpoint, investors will closely track productivity metrics such as output per man-shift and cost of production versus imported coal benchmarks. BCCL’s asset base is large, but valuation comfort will hinge on reserve quality, mine life visibility, and the extent to which pricing remains regulated versus market-linked. The IPO’s success will ultimately depend on disciplined pricing and credible operational reform. Markets today reward cash-flow resilience and execution visibility, not scale alone. If positioned correctly, BCCL offers exposure to a scarce, strategically critical segment of India’s industrial growth story, but investors will demand governance clarity alongside asset strength.” Harshal further added.
Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as “we”). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.
